Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.

November 17, 2023 0

AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc (ABBV) announced detailed results published in The Lancet evaluating …

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

November 16, 2023 0

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease …

About the FDA Approval of Eli Lilly’s Product Zepbound for Obesity

November 10, 2023 0

FDA Approval of Eli Lilly Product Zepbound for Obesity On Wednesday, Nov. 8, 2023, the U.S. …

Current News From Three Selected Biotech Firms

November 8, 2023 0

Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc (VRNA) announced that senior management …

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

November 6, 2023 0

CRISPR Therapeutics Data Presentation Announcement CRISPR Therapeutics (CRSP) today announced preclinical data from the Company’s investigational …

More Good News for Neurocrine Biosciences

November 3, 2023 0

Neurocrine Biosciences’ Product INGREZZA Improved Chorea Associated with Huntington's Disease Through Week 50 Yesterday, November 2, …

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

November 2, 2023 0

ImmunoGen in the NEWS Immunogen (IMGN) - a developer of antibody-drug conjugates (ADCs) for cancer treatment …

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

November 1, 2023 0

CRISPR Therapeutics and Vertex Pharmaceuticals NEWS CRISPR Therapeutics (CRSP) announced the completion of the U.S. Food …

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31, 2023 0

Beam Therapeutics in the NEWS Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to …

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer’s Disease

October 26, 2023 0

Anavex Life Sciences NEWS Anavex Life Sciences (AVXL) reported a new peer reviewed publication in journal Neurobiology of Aging, titled “Early treatment with …

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

October 24, 2023 0

Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference Indeed, today, Akero Therapeutics (AKRO) …

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

October 18, 2023 0

Intellia Therapeutics' NTLA-2001 Intellia Therapeutics' NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy …

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

October 14, 2023 0

Intellia Therapeutics Receives PRIME Designation from EMA Intellia Therapeutics (NTLA) announced that the European Medicines Agency …

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

October 11, 2023 0

Inovio Receives FDA Feedback for INO-3107 INOVIO (INO) - a biotechnology company focused on developing and …

Akero Therapeutics’ October 10, 2023 Press Release

October 10, 2023 0

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, …

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

October 9, 2023 0

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated …

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

October 6, 2023 0

Apellis Pharmaceuticals Launch Update of SYFOVRE® On October 5, 2023, Apellis Pharmaceuticals (APLS) provided an update …

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

October 5, 2023 0

Neurocrine Biosciences Announcement Today, Neurocrine Biosciences (NBIX) announced positive top-line data from the Phase 3 CAHtalyst™ …

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

October 4, 2023 0

Akero Therapeutics Akero Therapeutics (AKRO) announced publication in The Lancet Gastroenterology & Hepatology of results from …

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

September 28, 2023 0

Soleno Therapeutics Soleno Therapeutics (SLNO) is focused on the development and commercialization of novel therapeutics for …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

About the FDA Approval of Eli Lilly’s Product Zepbound for Obesity

Current News From Three Selected Biotech Firms

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

More Good News for Neurocrine Biosciences

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer’s Disease

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

Akero Therapeutics’ October 10, 2023 Press Release

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome